NCT06616155 2025-12-08Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerUniversity of Michigan Rogel Cancer CenterPhase 1/2 Recruiting39 enrolled
NCT03274778 2025-11-18Effect of Ruxolitinib on Tumor Infiltrating Myeloid CellsOncology Institute of Southern SwitzerlandPhase NA Withdrawn
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT00638378 2018-02-12Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate CancerIncyte CorporationPhase 2 Terminated22 enrolled 6 charts